Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88

Benzinga Newsdesk www.benzinga.com Positive 92.2%

Neg 0% Neu 0% Pos 92.2%

Leerink Partners analyst Thomas Smith maintains Celldex Therapeutics (NASDAQ:CLDX) with a Outperform and raises the price target from $70 to $88.